Faecalibacterium Prausnitzii Probiotic for Gut Inflammation Control

Composition for controlling growth of beneficial bacteria in the intestinal microbiota using human milk oligosaccharides (HMOs) and their constituent sugars. The composition can be used as a prebiotic or synbiotic to selectively promote growth of bacteria like Faecalibacterium, Akkermansia, Blautia, Subdoligranulum, Bilophila, and Sutterella. This can have applications in treating conditions like irritable bowel syndrome, inflammatory bowel disease, Parkinson's, cancer, cognitive decline, and atopic dermatitis by modulating the intestinal bacterial community. The HMOs can contain sugars like fucose, lactose, sialic acid, etc.

Source

Enhancing engraftment of beneficial gut bacteria in order to improve their therapeutic effectiveness. The technique involves co-administering a mucin-degrading bacterium along with a butyrate-producing bacterium. The mucin-degrading bacterium primes the gut environment for the butyrate-producing bacterium to engraft more efficiently. This synergistic engraftment enhancement allows better colonization of the butyrate-producing bacterium for improved therapeutic benefits. The technique can be used in microbiome therapies for conditions like metabolic disorders, skin disorders, neurological disorders, dysbiosis, inflammation, etc.

Source

Novel intestinal bacteria strains, vesicles derived from them, and endoplasmic reticulum (ER) fragments for use in treating inflammatory and bacterial diseases. The bacteria strains, isolated from the human gut, have anti-inflammatory and antibacterial properties. The vesicles and ER fragments from these strains also exhibit similar activities. The strains and derived products could be used to prevent, improve, or treat conditions like inflammatory bowel syndrome (IBS), irritable bowel disease (IBD), Clostridioides difficile infection (CDI), and bacterial infections.

Source

Antimicrobial compounds isolated from Faecalibacterium prausnitzii supernatants, comprising heat-stable secreted compounds with molecular weights less than 10 kDa, for inhibiting bacterial growth, preventing bacterial infection, and treating diseases such as irritable bowel disease, Crohn's disease, and ulcerative colitis.

Source

Therapeutic compositions comprising bacterial strains isolated from the human digestive tract for treating inflammatory and autoimmune disorders. The compositions comprise viable cells of the Mediterraneibacter faecis species, which enhance gut barrier function and reduce inflammation. The strains can be administered alone or in combination with anti-inflammatory agents or nutritional supplements to treat conditions such as inflammatory bowel disease.

Source

Microbial consortium comprising two or more microorganisms capable of modulating physiological processes in the host, including gut-brain axis, enteric nervous system, and metabolic pathways. The microorganisms produce specific metabolites, such as GABA, that modulate host physiological processes, including serotonin levels, gut barrier function, and inflammatory response. The consortium can be used to treat functional gastrointestinal disorders by enhancing gut health, reducing inflammation, and modulating neurotransmitter activity.

Source

A probiotic composition comprising a specific strain of Faecalibacterium prausnitzii (CNCM I-4573) for preventing and treating Clostridioides difficile (C. difficile) infections in individuals. The strain is administered orally or rectally to delay intestinal colonization by C. difficile, eliminate the bacteria from the intestine, and reduce symptoms associated with C. difficile infection. The composition can be administered simultaneously with or after antibiotic treatment and proton pump inhibitors (PPIs) to prevent C. difficile infection recurrence.

Source

Background and aims. Faecalibacterium prausnitzii, a highly abundant bacterium in the human gut microbiota, has been linked to overall health and is decreased in several pathological conditions, such as Inflammatory Bowel Disease (IBD). F. prausnitzii has shown anti-inflammatory properties in human and mouse models, notably through the induction of IL-10 signaling. Here, we investigated which cell types from human blood and intestinal tissue are responsible for producing IL-10 induced by F. prausnitzii, and providing the first mechanistic insights. Methods. Immune cells isolated from human blood and intestinal lamina propria of patients with IBD and non-inflamed controls, were stimulated them with F. prausnitzii EXL01 strain or Escherichia coli lipopolysaccharide (LPS) and analysed by Legendplex, ELISA, flow cytometry, RNA-sequencing (RNAseq), and Seahorse technology. Results. F. prausnitzii EXL01 strain induced the direct and dose-dependent production of IL-10 in CD14+ monocytes from the systemic circulation and intestinal tissue of IBD patients and non-inflamed controls, without in... Read More

Source

Sulfasalazine is a prodrug known to be effective for the treatment of inflammatory bowel disease (IBD)-associated peripheral spondyloarthritis (pSpA), but the mechanistic role for the gut microbiome in regulating its clinical efficacy is not well understood. Here, treatment of 22 IBD-pSpA subjects with sulfasalazine identifies clinical responders with a gut microbiome enriched in Faecalibacterium prausnitzii and the capacity for butyrate production. Sulfapyridine promotes butyrate production and transcription of the butyrate synthesis gene but in F. prausnitzii in vitro, which is suppressed by excess folate. Sulfasalazine therapy enhances fecal butyrate production and limits colitis in wild-type and gnotobiotic mice colonized with responder, but not non-responder, microbiomes. F. prausnitzii is sufficient to restore sulfasalazine protection from colitis in gnotobiotic mice colonized with non-responder microbiomes. These findings reveal a mechanistic link between the efficacy of sulfasalazine therapy and the gut microbiome with the potential to guide diagnostic and therapeutic approac... Read More

Source

<h3>Background</h3> Probiotics could protect against cancers, however, the roles of probiotics in inhibiting GC and affecting <i>H. pylori</i> infection are largely unclear. We first identified <i>Faecalibacterium prausnitzii</i> is depleted in GC. We aimed to evaluate the antitumorigenic function and molecular mechanism of <i>F. prausnitzii</i> in GC and its interplay with <i>H. pylori</i>. <h3>Methods</h3> <i>F. prausnitzii</i> abundance was determined in 1343 human subjects consisting of 48 healthy controls (HC), 192 superficial gastritis (SG), 130 atrophy gastritis (AG), 123 intestinal metaplasia (IM), 80 gastric epithelial dysplasia (GED), 456 cancer adjacent normal (CAN) and 407 GC. The effect of <i>F. prausnitzii</i> on GC was evaluated in GC cells, patient-derived organoids (G9T, POA145), human GC xenograft, YTN16 allografts and N -methyl- N -nitrosourea (MNU) induced GC tumorigenesis mouse models. <i>F. prausnitzii</i> attachment to GC cells and its impact on <i>H. pylori</i> colonization was determined by scanning electron microscopy (SEM) and transmission electron microsco... Read More

Source

The probiotic impact of microbes on host metabolism and health depends on both host genetics and bacterial genomic variation. Faecalibacterium prausnitzii is the predominant human gut commensal emerging as a next-generation probiotic. Although this bacterium exhibits substantial intraspecies diversity, it is unclear whether genetically distinct F. prausnitzii strains might lead to functional differences in the gut microbiome. Here, we isolated and characterized a novel F. prausnitzii strain (UT1) that belongs to the most prevalent but underappreciated phylogenetic clade in the global human population. Genome analysis showed that this butyrate-producing isolate carries multiple putative mobile genetic elements, a clade-specific defense system, and a range of carbohydrate catabolic enzymes. Multiomic approaches were used to profile the impact of UT1 on the gut microbiome and associated metabolic activity of C57BL/6 mice at homeostasis. Both 16S rRNA and metagenomic sequencing demonstrated that oral administration of UT1 resulted in profound microbial compositional changes including a s... Read More

Source

Faecalibacterium prausnitzii is one of the most prevalent commensals within the gut microbiota, being one of the gut's major butyrate-producing bacteria. Recent studies suggest a potential role for F. prausnitzii in exerting anti-tumorigenic effects. In the context of the phase II NADIM II clinical trial, a total of 81 baseline stool from locally advanced non-small cell lung cancer (NSCLC) patients randomized into the experimental arm (neoadjuvant nivolumab plus chemotherapy followed by adjuvant nivolumab, n=55) or the control arm (chemotherapy alone, n=26) were collected. DNA was extracted using the QIAamp PowerFecal DNA Kit (Qiagen) and analyzed by QPCR using specific primers for F. prausnitzii strain ATCC 27768. In the experimental arm, the presence of F.prautnizzi was significantly associated with improved overall survival (HR: 0.24; 95CI: 0.08-0.76; P=0.015), and a trend was noted toward progression-free survival (HR: 0.46; 95IC: 0.18-1.19; P=0.1). Specifically, patients with detected F. prausnitzii in their fecal sample (n=46) exhibited a 88% probability of being alive and 68% ... Read More

Source

Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases with uncertain etiology. We aimed to determine the amounts of Akkermansia muciniphila and Faecalibacterium prausnitzii in the intestinal microbiota of these patients and to correlate their amounts with blood IL-8, IL-10, and IL-12 cytokine levels.

Source

A composition for diagnosing and treating inflammatory diseases, such as inflammatory bowel disease (IBD), comprising a Faecalibacterium spp. microorganism. The composition can be used to predict the risk of developing IBD, diagnose IBD, or evaluate the effectiveness of IBD treatment. The microorganism, specifically Faecalibacterium cancerinhibens, has anti-inflammatory properties and can be administered orally to prevent or treat IBD.

Source

A Parabacteroides distasonis strain deposited under accession number CNCM I-5828, isolated from human feces, exhibits strong efficacy in preventing or treating visceral pain associated with Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). The strain can be used in nutritional supplements or as a medicament, particularly for visceral pain management.

Source

A novel strain of Faecalibacterium prausnitzii, designated KBL1027, having accession number KCTC14231BP, with anti-inflammatory properties and the ability to induce production of anti-inflammatory cytokines. The strain can prevent, improve, or treat inflammatory diseases, including inflammatory bowel disease, atopic dermatitis, and allergic diseases, by modulating the gut microbiota and enhancing the intestinal barrier function.

Source

A novel strain of Faecalibacterium prausnitzii, designated EB-FPDK9, exhibiting anti-inflammatory and lipid accumulation inhibitory effects. The strain is isolated from human intestinal mucus and characterized by its 16S rRNA sequence. EB-FPDK9 is effective in preventing or treating inflammatory diseases, liver disease, and metabolic disorders, and can be administered as a pharmaceutical composition or incorporated into food products.

Source

The human gut microbiota has gained interest as an environmental factor that may contribute to health or disease1. The development of next-generation probiotics is a promising strategy to modulate the gut microbiota and improve human health; however, several key candidate next-generation probiotics are strictly anaerobic2 and may require synergy with other bacteria for optimal growth. Faecalibacterium prausnitzii is a highly prevalent and abundant human gut bacterium associated with human health, but it has not yet been developed into probiotic formulations2. Here we describe the co-isolation of F. prausnitzii and Desulfovibrio piger, a sulfate-reducing bacterium, and their cross-feeding for growth and butyrate production. To produce a next-generation probiotic formulation, we adapted F. prausnitzii to tolerate oxygen exposure, and, in proof-of-concept studies, we demonstrate that the symbiotic product is tolerated by mice and humans (ClinicalTrials.gov identifier: NCT03728868 ) and is detected in the human gut in a subset of study participants. Our study describes a technology for t... Read More

Source

Abstract In humans, many diseases are associated with alterations in gut microbiota, namely increases or decreases in the abundance of specific bacterial groups. One example is the genus Faecalibacterium. Numerous studies have underscored that low levels of Faecalibacterium are correlated with inflammatory conditions, with inflammatory bowel disease (IBD) in the forefront. Its representation is also diminished in the case of several diseases, including colorectal cancer (CRC), dermatitis, and depression. Additionally, the relative presence of this genus is considered to reflect, at least in part, intestinal health status because Faecalibacterium is frequently present at reduced levels in individuals with gastrointestinal diseases or disorders. In this review, we first thoroughly describe updates to the taxonomy of Faecalibacterium, which has transformed a single-species taxon to a multispecies taxon over the last decade. We then explore the links discovered between Faecalibacterium abundance and various diseases since the first IBD-focused studies were published. Next, we examine cur... Read More

Source

Microbial consortia for treating diseases by degrading disease-associated metabolic substrates in the gastrointestinal tract. The consortia comprise a plurality of active microbes that metabolize the substrate, along with a supportive community of microbes that metabolize byproducts produced by the active microbes. The consortia exhibit enhanced characteristics, including improved gastrointestinal engraftment, increased biomass, and enhanced substrate metabolism, compared to administering the active microbes alone.

Source

A composition for treating dysbiosis-related conditions comprising two purified bacterial populations: a long-term engrafting population and a transient engrafting population. The long-term population includes bacteria with specific 16S rDNA sequences, while the transient population includes bacteria with specific functional features such as anti-inflammatory activity, bile acid production, and epithelial integrity restoration. The composition is designed to provide a consistent and stable product for treating conditions like inflammatory bowel disease and cancer.

Source

Abstract Faecalibacterium prausnitzii is a promising biomarker of a healthy human microbiota. However, previous studies reported the heterogeneity of this species and found the presence of several distinct groups at the species level among F. prausnitzii strains. Our recent study revealed that methods previously developed for quantification of F. prausnitzii were not specific to the species level because of the heterogeneity within the F. prausnitzii species and the application of 16S rRNA gene, which is an invalid genetic marker for the species. Therefore, previously available data failed to provide information on different groups, which limits our understanding of the importance of this organism for host health. Here, we propose an alternative gene marker for quantification of F. prausnitzii-related taxa. A total of nine group-specific primer pairs were designed by targeting rpoA gene sequences. The newly developed rpoA-based qPCR successfully quantified targeted groups. Application of the developed qPCR assay in six healthy adults revealed marked differences in abundance and preva... Read More

Source

Probiotics and metabolites (postbiotics) in preparing products for relieving colorectal inflammation. The mixture includes five self-isolated and identified probiotics, their fermentation metabolites and bacterial composition formulations for clinical prevention and treatment of colorectal-associated inflammatory bowel disease.

Source

Purpose: Additional effective therapeutic strategies for Type 2 diabetes (T2D) patients are urgently needed. Gut microbiota plays an important role in T2D development and is a promising treatment strategy for T2D patients. Faecalibacterium prausnitzii (F. prausnitzii) is regarded as one of the most important bacterial indicators for a healthy gut, but the mechanisms of its anti-diabetic properties are still unclear. Methods and Results: The abundance of F. prausnitzii in feces of patients with T2D was detected by using qPCR. The effects of F. prausnitzii on glucose homeostasis, insulin resistance (IR), dyslipidemia, hepatic steatosis and inflammation were investigated in type 2 diabetic (T2D) db/db mice. We also investigated F. prausnitzii in people. Our results showed that the abundance of F. prausnitzii was significantly lower in T2D patients compared to healthy subjects. In T2D mice, we found that F. prausnitzii treatment significantly decreased fasting blood glucose and IR index, indicating improved glucose intolerance as well as IR. Furthermore, based on evaluation of lipid-regu... Read More

Source

Use of Faecalibacterium bacteria, particularly Faecalibacterium prausnitzii, to prevent or treat respiratory virus infections, including COVID-19 and influenza, by reducing viral load and mitigating lung damage. The bacteria can be administered live or inactivated, and can be used as a standalone treatment or in combination with other therapies.

Source

Faecalibacterium prausnitzii (F. prausnitzii) is a bacterial taxon in the human gut with anti-inflammatory properties, and this may contribute to the beneficial effects of healthy eating habits. However, little is known about the nutrients that enhance the growth of F. prausnitzii other than simple sugars and fibers. Here, we combined dietary and microbiome data from the American Gut Project (AGP) to identify nutrients that may be linked to the relative abundance of F. prausnitzii. Using a machine learning approach in combination with univariate analyses, we identified that sugar alcohols, carbocyclic sugar, and vitamins may contribute to F. prausnitzii growth. We next explored the effects of these nutrients on the growth of two F. prausnitzii strains in vitro and observed robust and strain-dependent growth patterns on sorbitol and inositol, respectively. In the context of a complex community using in vitro fermentation, neither inositol alone nor in combinations with vitamin B exerted a significant growth-promoting effect on F. prausnitzii, partly due to high variability among the f... Read More

Source

Microbial-based therapies for treating neurological and metabolic disorders. The therapies involve administering a composition of isolated and purified microbes that increase production of butyrate in the subject. The microbes can be selected based on their ability to modulate nervous system receptors, neurotransmitters, and metabolic pathways. The composition can be formulated as an oral capsule or pill.

Source

Faecalibacterium represents one of the most abundant bacterial groups in the human intestinal microbiota of healthy adults and can represent more than 10% of the total bacterial population, Faecalibacterium prausnitzii being the only recognized species up to the past year. Reduction in the abundance of F. prausnitzii in the human gut has been linked to several human disorders, such as Crohn's disease. In this study, we developed a strategy to modify the relative abundance of F. prausnitzii in fecal microbiotas as a means of evaluating its contribution to the immunomodulatory effect of intestinal microbiotas with different F. prausnitzii contents using a peripheral blood mononuclear cell (PBMC) model. We used a polyclonal antibody against the surface of F. prausnitzii M21 to capture the bacterium from synthetic and human fecal microbiotas using immunoseparation techniques. As a proof-of-principle study, the levels of immunomodulation exerted by microbiotas of healthy donors (HDs) with different relative abundances of F. prausnitzii, achieved with the above-mentioned immunoseparation t... Read More

Source

A composition for treating inflammatory gastrointestinal diseases, comprising an association of mesalamine or a derivative thereof with a bacterial strain of Faecalibacterium prausnitzii (CNCM I-4573). The composition synergistically reduces gastrointestinal inflammation, particularly in inflammatory bowel diseases, by combining the anti-inflammatory properties of mesalamine with the beneficial effects of the F. prausnitzii strain.

Source

Abstract Background There is insufficient knowledge about the key characteristics of the pathogenic and protective bacteria in inflammatory bowel disease. The ENIGMA study aimed to identify the phylogenetic and functional characteristics of Faecalibacterium prausnitzii, considered a protective anti-inflammatory bacterium, in both health and Crohns disease in populations in the West (high Crohns incidence) and Hong Kong (rapidly increasing Crohns incidence). Methods Total DNA was extracted from tissue (right colon and terminal ileum) and stool collected from case-control cohorts in Hong Kong (n=51; 30 Crohns, 21 controls) and Australia (n=49; 29 Crohns, 20 controls). In parallel, the colonic mucosa-associated microbiota (MAM) for each subject was cultured from anaerobically preserved tissue. Shotgun metagenomic sequencing was used to characterise the stool and colonic MAM, augmented with 16S rRNA gene profiling and F. prausnitzii qPCR. The HUMANn3 and/or QIIME2 packages were used for the taxonomic and/or functional characterisation of the datasets. Metagenome-assembled genomes ... Read More

Source

Faecalibacterium prausnitzii is a beneficial human gut microbe and a candidate for next-generation probiotics. With probiotics now being used in clinical treatments, concerns about their safety and side effects need to be considered. Therefore, it is essential to obtain a comprehensive understanding of the genetic diversity, functional characteristics, and potential risks of different F. prausnitzii strains. In this study, we collected the genetic information of 84 F . prausnitzii strains to conduct a pan-genome analysis with multiple perspectives. Based on single-copy genes and the sequences of 16S rRNA and the compositions of the pan-genome, different phylogenetic analyses of F. prausnitzii strains were performed, which showed the genetic diversity among them. Among the proteins of the pan-genome, we found that the accessory clusters made a greater contribution to the primary genetic functions of F. prausnitzii strains than the core and specific clusters. The functional annotations of F. prausnitzii showed that only a very small number of proteins were related to human diseases and... Read More

Source

During the taxonomic analysis of intestinal microbiota samples of patients with various types of cancer undergoing immunotherapy potential biological markers, such as Faecalibacterium prausnitzii associated with a positive outcome of treatment and E. oli with a negative outcome were identified.

Source

Introduction The commensal bacterium Faecalibacterium prausnitzii is a prominent member of the microbiome of animals and humans, and it plays an important role in several physiological processes. Numerous studies have correlated the reduction of F. prausnitzii abundance with many disease states, including irritable bowel syndrome, Crohns disease, obesity, asthma, major depressive disorder, and metabolic diseases in humans. Studies have also correlated F. prausnitzii with diseases in humans involved in altered glucose metabolism, including diabetes. Research design and methods The aim of this study was to investigate the effects of compositions derived from three strains of F. prausnitzii (coined FPZ) on glucose metabolism in diet-induced obese male C57BL/6J prediabetic and type 2 diabetic mice. The primary endpoints of these studies were measuring changes in fasting blood glucose, glucose tolerance (as measured by a glucose tolerance test), and percent hemoglobin A1c (HbA1c) with longer term treatment. Two placebo-controlled trials were carried out using both live cell FPZ and kille... Read More

Source

&lt;div&gt;Abstract&lt;p&gt;Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy; however, their application is limited by the occurrence of immune-related adverse events. The gut microbiota plays important roles in the response to and toxicity of immunotherapy and &lt;i&gt;Faecalibacterium prausnitzii&lt;/i&gt; (&lt;i&gt;F. prausnitzii&lt;/i&gt;) has been shown to possess immunomodulatory potential. Here, we found that patients receiving ICIs who developed colitis had a lower abundance of &lt;i&gt;F. prausnitzii&lt;/i&gt;. &lt;i&gt;In vivo&lt;/i&gt;, immunocompetent mice administered with dextran sodium sulfate and immunodeficient NSG mice with human peripheral blood mononuclear cell transfer were treated with ICIs to study ICI-induced colitis. Dual CTLA4 and PD-1 blockade exacerbated autoimmune colitis, activated an inflammatory response, and promoted myeloid cell infiltration, with higher percentages of macrophages, dendritic cells, monocytes, and neutrophils. &lt;i&gt;F. prausnitzii&lt;/i&gt; administration mitigated the exacerbated colitis induced by ICIs. Conco... Read More

Source

Probiotics are live microorganisms that act as food supplements that have beneficial effects within-host by influencing and establishing a friendly gut microflora. The most common commercially available probiotic strains belong to the species of Lactobacillus and Bifidobacterium. The human gastrointestinal tract is also a reservoir of probiotic organisms. Alteration of the gut microbiota often leads to the disruption of hostmicrobial interactions and influences disease conditions (dysbiosis). Gut microflora with enriched probiotic organisms has profound impacts on immune function, digestion, and metabolism. Recently, the term "next-generation probiotics" has been introduced to describe some new strains, namely, Akkermansia, Bacteroides, Faecalibacterium, and sometimes genetically modified organisms. The prospect of such probiotics has been discussed in this chapter.

Source

Introduction Inflammatory bowel diseases (IBDs) are associated with both immune abnormalities and dysbiosis, characterized by a loss of Faecalibacterium prausnitzii (F. prausnitzii). However, the reason for F. prausnitzii deficiency remains unclear. Methods 16S rDNA sequencing and IgA enzyme-linked immunosorbent assay (ELISA) were applied to identify bacterial community and IgA changes in ulcerative colitis (UC) patients. Forced immunization with F. prausnitzii in rabbits was conducted. To screen for potential IgA-reactive proteins in F. prausnitzii lysates, we performed western blotting and mass spectrometry analyses. Pyruvate: ferredoxin oxidoreductase (PFOR) was cloned and purified, then the immunoreactivity of PFOR was verified in peripheral blood mononuclear cells (PBMCs) through PCR, ELISpot assay and single-cell sequencing (scRNA-seq). Finally, the UC fecal dysbiosis was re-analyzed in the context of the phylogenetic tree of PFOR. Results F. prausnitzii was underrepresented in UC patients with elevated F. prausnitzii-reactive IgA in the fecal supernatant. Forced immunization ... Read More

Source

Faecalibacterium prausnitzii is abundant in the healthy human intestinal microbiota, and the absence or scarcity of this bacterium has been linked with inflammatory diseases and metabolic disorders. F . prausnitzii thus shows promise as a next-generation probiotic for use in restoring the balance of the gut microbial flora and, due to its strong anti-inflammatory properties, for the treatment of certain pathological conditions. However, very little information is available about gene function and regulation in this species. Here, we utilized a systems biology approachweighted gene co-expression network analysis (WGCNA)to analyze gene expression in three publicly available RNAseq datasets from F . prausnitzii strain A2-165, all obtained in different laboratory conditions. The co-expression network was then subdivided into 24 co-expression gene modules. A subsequent enrichment analysis revealed that these modules are associated with different kinds of biological processes, such as arginine, histidine, cobalamin, or fatty acid metabolism as well as bacteriophage function, molecular ch... Read More

Source

A composition for treating and preventing inflammatory gastrointestinal diseases, particularly inflammatory intestinal disorders, comprising a combination of Faecalibacterium prausnitzii and Christensenella minuta or Christensenella timonensis bacterial strains, or their culture supernatants, in a physiologically acceptable medium. The composition exhibits synergistic anti-inflammatory properties, reducing pro-inflammatory molecule production, particularly interleukin 8 (IL-8), and is suitable for oral or rectal administration.

Source

The gut microbiome is home to thousands of species of bacteria, that are essential for human digestion, immunity, and physiology.Faecalibacterium prausnitzii makes up about 5% of a healthy human gut microbiome and a lower abundance of this bacterium has been found in patients with IBD and Crohn's disease.Among an extensive repertoire of carbohydrate active enzymes, F. prausnitzii has 2 GH31 -glycosidases, which are from the same family as Sucrase-Isomaltase and Maltase-Glucoamylase, human digestive enzymes with overlapping and distinguishing substrate specificities.This project aims to characterize the substrate specificity and preference of F. prausnitzii GH31 -glycosidases to better understand the structural features of GH31 enzymes and the biological capabilities of these bacteria.AlphaFoldV2.1.0was used to create computational models of F. prausnitzii glycosidases, and the substrate specificity and kinetics parameters are reported.Structurally, these -glycosidases have the same identified conserved N-terminal and (/)8 barrel domains, but FpAG1 has an additional conserved do... Read More

Source

Evidence linking Faecalibacterium prausnitzii abundance to nonalcoholic fatty liver disease (NAFLD) is accumulating; however, the causal relationship remains obscure. In this study, 12 F. prausnitzii strains were orally administered to high fat diet fed C57BL/6J mice for 12 weeks to evaluate the protective effects of F. prausnitzii on NAFLD. We found that five F. prausnitzii strains, A2-165, LB8, ZF21, PL45, and LC49, significantly restored serum lipid profiles and ameliorated glucose intolerance, adipose tissue dysfunction, hepatic steatosis, inflammation, and oxidative stress in a mouse model of NAFLD. Moreover, two strains, LC49 and LB8, significantly enhanced short-chain fatty acid (SCFA) production and modulated the gut microbiota. Based on the combined analysis of linear discriminant analysis effect size and microbial communities, the core microbiome related to NAFLD comprised Odoribacter, Roseburia, Erysipelatoclostridium, Tyzzerella, Faecalibaculum, Blautia, and Acetatifactor, and the last five genera can be reversed by treatment with the LC49 and LB8 strains. Additionally, t... Read More

Source

Compositions and methods for treating liver disorders by administering a consortium of isolated and purified microbial populations that improve gut function and reduce liver enzyme levels. The microbial populations, which can include species such as Akkermansia muciniphila and Faecalibacterium prausnitzii, are administered in an effective amount to reduce serum levels of liver enzymes AST and ALT by at least 5 IU/L. The compositions can be formulated in an ingestible form and administered orally, and can be used to treat a range of liver disorders including nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), liver fibrosis, and cirrhosis.

Source

A composition comprising specific bacteria identified in patients responding to immune checkpoint inhibitors, which can be used as a treatment for cancer and other diseases, or as a diagnostic to predict response to checkpoint inhibitors. The composition comprises one or more bacterial isolates from species such as Bifidobacterium, Faecalibacterium, and Bacteroides, which have been shown to modulate the gut microbiome and enhance anti-tumor immune responses. The composition can be used alone or in combination with checkpoint inhibitors to increase treatment efficacy, and can also be used as a predictive biomarker to identify patients who will respond to checkpoint inhibitors.

Source

Abundance of Faecalibacterium prausnitzii, a dominant bacterium of the human microbiota that exhibits antiinflammatory effects, is decreased in patients with inflammatory bowel diseases (IBD). In humans, colonic lamina propria contains IL-10-secreting, Foxp3- Tregs characterized by a double expression of CD4 and CD8 (DP8) and a specificity for F. prausnitzii. This Treg subset is decreased in IBD. The in vivo effect of DP8 cells has not been evaluated yet to our knowledge. Here, using a humanized model of a NSG immunodeficient mouse strain that expresses the HLA D-related allele HLA-DR*0401 but not murine class II (NSG-Ab DR4) molecules, we demonstrated a protective effect of a HLA-DR*0401-restricted DP8 Treg clone combined with F. prausnitzii administration in a colitis model. In a cohort of patients with IBD, we showed an independent association between the frequency of circulating DP8 cells and disease activity. Finally, we pointed out a positive correlation between F. prausnitzii-specific DP8 Tregs and the amount of F. prausnitzii in fecal microbiota in healthy individuals ... Read More

Source

Therapeutic compositions for treating dysbiosis, comprising isolated bacteria that inhibit the growth of pathogenic bacteria, and methods for preparing these compositions. The compositions comprise at least one isolated bacterium, preferably a spore-forming bacterium, that is antagonistic towards an intestinal bacterium, inhibits its growth, or neutralizes its toxin. The compositions can be used to treat various forms of dysbiosis, including those associated with enteric bacterial infections, inflammatory bowel disease, and metabolic disorders.

Source

Faecalibacterium prausnitzii is one of the most abundant commensals of gut microbiota that is not commonly administered as a probiotic supplement. Being one of the gut's major butyrate-producing bacteria, its clinical significance and uses are on the rise and it has been shown to have anti-inflammatory and gut microbiota-modulating properties in the treatment of inflammatory bowel illness, Crohn's disease, and colorectal cancer. Colorectal cancer (CRC) is a silent killer disease that has become one of the leading causes of cancer-related death worldwide. This study aimed to evaluate the anti-tumorigenic and antiproliferative role of F. prausnitzii as well as to study its effects on the diversity of gut microbiota in rats. Findings showed that F. prausnitzii probiotic significantly reduced the colonic aberrant crypt foci frequency and formation in Azoxymethane (AOM)-induced CRC in rats. In addition, the administration of F. prausnitzii lowered the lipid peroxidation levels in the colon tissues. For in vitro 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay, the... Read More

Source

Treating immune checkpoint inhibitor (ICI)-associated colitis by administering fecal matter from a healthy donor or a composition comprising specific populations of bacteria, including Escherichia, Akkermansia, Bacteroides, and others, to modify the gut microbiome and alleviate symptoms.

Source

Parabacteroides distasonis strains CNCM 1-5576 and CNCM 1-5578 for treating and preventing gastrointestinal diseases, including inflammatory bowel disease and obesity, by reducing inflammation and restoring gut barrier function. The strains, isolated from neonatal gut microbiota, exhibit anti-inflammatory and barrier-restoring properties in vitro and in vivo models of colitis and obesity. They can be administered in live or heat-inactivated form, and are suitable for oral administration in food products, supplements, or pharmaceutical formulations.

Source

Compositions of isolated bacterial strains that can be used to decrease susceptibility to infection and/or that facilitate restoration of a healthy gut microbiota. The compositions contain a combination of bacterial strains that are capable of synergistically inhibiting pathogenic bacteria. The strains are selected based on their ability to form spores and their functional properties. The compositions can be administered orally or rectally to populate the gut with beneficial bacteria that can outcompete pathogens.

Source

A novel Faecalibacterium prausnitzii strain, EB-FPDK11, exhibiting anti-inflammatory and lipid accumulation inhibitory effects, is disclosed for preventing or treating inflammatory diseases, liver diseases, and metabolic diseases. The strain can be administered as a pharmaceutical composition or incorporated into food products to provide therapeutic benefits.

Source

Faecalibacterium prausnitzii has been suggested as a biomarker of a healthy microbiota in human adults. Here, we report a taxonomic study of F. prausnitzii using genomic information and evaluation of the quantitative real-time PCR (qPCR) assay by focusing on specific primers to quantify its population. Average nucleotide identity values revealed that strains deposited as F. prausnitzii in a public database were separated into eight genomogroups with significant differences at the species level. A total of six of the 10 primer pairs used in the previous studies for qPCR of F. prausnitzii contained sequence mismatches to 16S rRNA gene sequences of the tested strains with markedly different levels by in silico analysis. In vitro primer evaluation by qPCR generally agreed with the in silico analysis, and markedly reduced amount of DNA was recorded by qPCR in combination with the primer pairs containing sequence mismatches. The present study demonstrated that a part of the accumulated knowledge on F. prausnitzii is maybe based on biased results.

Source